{
   "title": "Celgene 's top product revenues 2013 to 2018",
   "labels": [
      "Product Name",
      "2013",
      "2014",
      "2015",
      "2016",
      "2017",
      "2018"
   ],
   "columnType": "multi",
   "graphType": "bar",
   "summaryType": "baseline",
   "summary": [
      "This grouped bar chart shows Revenue in million USD on the Y-axis for 5 different Product Names for 6 groups 2013, 2014, 2015, 2016, 2017, and 2018 that are presented on the X-axis. ",
      " Out of all 6 groups, 2016 had the highest Revenue in million USD for Product Name Revlimid (cancer) and 2013 had the lowest Revenue in million USD for Product Name Otezla (psoriasis). ",
      "Product Name Revlimid (cancer) and Otezla (psoriasis) had the biggest gap of 42802.0 between the highest and lowest Revenue in million USD found for 2013. ",
      "Averaging all 6 groups 2013, 2014, 2015, 2016, 2017, and 2018, the Product Name Revlimid (cancer) is the maximum Revenue in million USD and Other is the minimum Revenue in million USD. "
   ],
   "xAxis": "Product Name",
   "yAxis": "Revenue in million USD",
   "min_summary": [
      "This grouped bar chart represents 5 different Product Names on X-axis for 6 groups 2013, 2014, 2015, 2016, 2017, and 2018. On the Y-axis it shows their corresponding Revenue in million USD. ",
      " For Product Name Revlimid (cancer), 2016 had the highest Revenue in million USD 69736.0 among the 6 groups and in Otezla (psoriasis), 2013 had the lowest Revenue in million USD 0.0. "
   ],
   "mid_summary": [
      "This grouped bar chart shows Revenue in million USD on the Y-axis for 5 different Product Names for 6 groups 2013, 2014, 2015, 2016, 2017, and 2018 that are presented on the X-axis. ",
      " Out of all 6 groups, 2016 had the highest Revenue in million USD for Product Name Revlimid (cancer) and 2013 had the lowest Revenue in million USD for Product Name Otezla (psoriasis). ",
      "Product Name Revlimid (cancer) and Otezla (psoriasis) had the biggest gap of 42802.0 between the highest and lowest Revenue in million USD found for 2013. ",
      "Averaging all 6 groups 2013, 2014, 2015, 2016, 2017, and 2018, the Product Name Revlimid (cancer) is the maximum Revenue in million USD and Other is the minimum Revenue in million USD. "
   ],
   "max_summary": [
      "This grouped bar chart shows Revenue in million USD on the Y-axis for 5 different Product Names for 6 groups 2013, 2014, 2015, 2016, 2017, and 2018 that are presented on the X-axis. ",
      " For Product Name Revlimid (cancer), 2016 had the highest Revenue in million USD 69736.0 among the 6 groups and in Otezla (psoriasis), 2013 had the lowest Revenue in million USD 0.0. ",
      " Among all the Product Names, 2013 had the highest Revenue in million USD 42803.0 in Product Name Revlimid (cancer) and lowest value 0.0 in Product Name Otezla (psoriasis). ",
      " There is a gap of 42802.0 between the highest and lowest Revenue in million USD found for 2013 in Product Name Revlimid (cancer) and Otezla (psoriasis). ",
      " Among the groups, 2016 had the biggest difference in Revenue in million USD. Where the maximum Revenue in million USD was 69736.0 times larger than the minimum Revenue in million USD. ",
      " In case of Product Name Revlimid (cancer), 2016 had the highest Revenue in million USD 69736.0 among the 6 groups and in Otezla (psoriasis), 2013 had the lowest Revenue in million USD 0.0. The second highest Revenue in million USD 8482.0 was observed for 2016 in Product Name Revlimid (cancer). ",
      "On average, the Product Name Revlimid (cancer) had the highest Revenue in million USD for all 6 groups 2013, 2014, 2015, 2016, 2017, and 2018. Whereas Other had the lowest average Revenue in million USD. "
   ],
   "trends": [
      {},
      {
         "2": [
            "0",
            "0"
         ],
         "13": [
            "6",
            "0"
         ]
      },
      {
         "2": [
            "0",
            "1"
         ],
         "14": [
            "6",
            "1"
         ]
      },
      {}
   ],
   "data": [
      {
         "Product Name": "Revlimid (cancer)",
         "2013": "4280.3",
         "2014": "4980",
         "2015": "5801.1",
         "2016": "6973.6",
         "2017": "8187",
         "2018": "9685"
      },
      {
         "Product Name": "Pomalyst/Imnovid (cancer)",
         "2013": "305.4",
         "2014": "679.7",
         "2015": "983.3",
         "2016": "1310.7",
         "2017": "1614",
         "2018": "2040"
      },
      {
         "Product Name": "Otezla (psoriasis)",
         "2013": "0",
         "2014": "69.8",
         "2015": "471.7",
         "2016": "1017.2",
         "2017": "1279",
         "2018": "1608"
      },
      {
         "Product Name": "Abraxane (cancer)",
         "2013": "648.9",
         "2014": "848.2",
         "2015": "967.5",
         "2016": "973.4",
         "2017": "992",
         "2018": "1062"
      },
      {
         "Product Name": "Other",
         "2013": "0",
         "2014": "0",
         "2015": "0",
         "2016": "0",
         "2017": "901",
         "2018": "870"
      }
   ]
}